Skip to content

Feasibility and Preliminary Clinical Effects of Exercise Training During Neoadjuvant Therapy for Lung Cancer

Feasibility and Preliminary Clinical Effects of Exercise Training During Neoadjuvant Therapy for Lung Cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500106456
Enrollment
Unknown
Registered
2025-07-24
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

intervention group:The intervention group will receive an 8- to 12-week exercise training program in addition to standard care.
control subjects:The control group will receive standard care, including regular health education based on routine treatment. The health education will cover topics such as balanced diet, lifestyle mo

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed NSCLC stage IB–IIIB (N2); 2. Age >=18 years; 3. Patient has been evaluated by a multidisciplinary team and is scheduled to receive neoadjuvant immunotherapy or chemoimmunotherapy (PD-1/PD-L1 inhibitors) followed by surgery; 4. Body Mass Index (BMI) >=18.5 and self-reported weight loss <10% within the past month; 5. ECOG performance status (PS) <=2; 6. No contraindications to exercise training, such as myocardial infarction or stroke within the past 6 months, chronic heart failure, unstable angina, severe arrhythmias, significant left ventricular dysfunction, acute pulmonary embolism, severe peripheral vascular disease or limb dysfunction; 7. Willingness to participate and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Evidence of distant metastasis or other malignancies on imaging; 2. Inability to cooperate due to mental illness, consciousness disorder, or cognitive impairment; 3. Unable to tolerate exercise training; 4. Presence of any contraindications to physical activity (e.g., myocardial infarction or stroke within 6 months, chronic heart failure, unstable angina, severe arrhythmias, significant left ventricular dysfunction, acute pulmonary embolism, severe peripheral vascular disease or limb dysfunction); 5 Other exercise-related contraindications such as active hemoptysis or untreated pneumothorax; 6. Pregnant or breastfeeding individuals; 7. Unwillingness or inability to comply with study requirements; 8. Daily activity level >=6 METs; 9. BMI =10% self-reported weight loss in the past month.

Design outcomes

Primary

MeasureTime frame
VO2 peak;

Secondary

MeasureTime frame
Exercise endurance;Physical activity level;Immune function indicators;Treatment toxicity;Treatment completion;Quality of life and emotional stress;

Countries

China

Contacts

Public ContactHongjuan Li

West China Hospital, Sichuan University

604638284@qq.com+86 189 8060 6961

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026